Liposomal doxorubicin regimens, Dexrazoxane hydrochloride, gliflozins (SGLT-2i) [56], and Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors [57] exert significant improvements of cardiac functions in cancer patients treated with anthracyclines but more randomized trials are needed to confirm this point. The gene discussed is PCSK9; the disease is cancer.